Interferon beta treatment of MS in the daily clinical setting: A 3-year post-marketing study

Neurological Sciences

Volumn 24, Issue 5, 2003, Pages 340-345

  Onesti, E ^a   Bagnato, F ^a   Tomassini, V ^a   Volante, G ^a   Denaro, F ^a   Frontoni, M ^a   Millefiorini, E ^a   Pozzilli, C ^a   Fieschi, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Efficacy; Interferon beta; Multiple sclerosis; Post marketing study; Relapse

Indexed keywords

BETA INTERFERON; INTERFERON BETA SERINE; INTERFERON BETA-1B; PLACEBO;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISABILITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; ITALY; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTPATIENT CARE; OUTPATIENT DEPARTMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTMARKETING SURVEILLANCE; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; SAFETY; SCORING SYSTEM; SPASTICITY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE FACILITIES; COHORT STUDIES; DISABILITY EVALUATION; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; ITALY; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PRODUCT SURVEILLANCE, POSTMARKETING; RECURRENCE; RETROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME;

EID: 0348229149     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-003-0186-z     Document Type: Article

References (17)

1. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4):655-661
2. Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43(4):662-667
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
4. Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E, Galgani S, Buttinelli C, Perciaccante G, Piazza G, Bozzao L, Fieschi C (1996) Magnetic resonance imaging changes with recombinant human interferon-beta-1 a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 61:251-258
5. The Danish Multiple Sclerosis Group (2000) The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. Mult Scler 6(3):172-175
6. The Danish Multiple Sclerosis Group (1996) Autorizzazione alla immissione in commercio della specialità medicinale Betaferon. Decreto Ministeriale del 5 Febbraio 1996. Gazzetta Ufficiale n. 41, 19 February 1996
7. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227-231
8. MS Study Group of the City of Valencia (1997) Interferon-beta 1b in the treatment of remittent-recurrent multiple sclerosis. Clinical experience of the Valencia group. Rev Neurol 25(148):1876-1879
9. Milanese C, La Mantia L, Palumbo R (1999) Interferon beta treatment in relapsing-remitting multiple sclerosis: a postmarketing study in Lombardia, Italy. Multiple Sclerosis Centers of Lombardia, Italy. Ital J Neurol Sci 30:297-302
10. Weinshenker BG (1995) The natural history of multiple sclerosis. Neurol Clin 13(1):119-146
11. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45(7):1277-1285
12. Mohr DC, Likosky W, Boudewyn AC, Marietta P, Dwyer P, Van der Wende J, Goodkin DE (1998) Side effect profile and adherence in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 4:487-489
13. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770-782
14. Casanova B, Coret F, Valero C, Landete L, Pascual A, Vilchez JJ (2002) High clinical inflammatory activity prior to the development of secondary progression: a prospective 5-year follow-up study. Mult Scler 8:59-63
15. Koudriavtseva T, Pozzilli C, Fiorelli M, Gasperini C, Bagnato F, Galgani S, Frontoni M, Ciccarelli O, Bastianello S (1998) Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis. Mult Scler 4:403-407
16. Munschauer FE, Kinkel RP (1997) Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 19:883-893
17. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS (1996) Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 46:12-18